secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001193125-24-036224
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

KalVista terminates $100M ATM sales agreement with Cantor Fitzgerald; no shares sold
--------------------------------------------------------------------------------

- Terminated Controlled Equity Offering Sales Agreement with Cantor, effective Feb 14, 2024.
- Agreement allowed up to $100M in common stock sales; company sold zero shares under it.
- Cantor waived notice period, making termination immediate upon close of business Feb 14.
- Termination has no effect on operations or capital; company retains other financing avenues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000119312524036224/0001193125-24-036224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000119312524036224/d771919d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-036224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer